How do you think about sequencing therapy for a patient with ALK+ metastatic NSCLC given the available options?   

What is the current data regarding acquired resistance mutations for ALK? 

Should newer agents such as lorlatinib be reserved for later lines as a means of overcoming resistance, or started in front-line?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at NYU Winthrop Hospital
Great review!
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution